Is Moderna Inc (MRNA) overvalued? · rev $1.94B
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stephane Bancel.
This page asks whether Moderna Inc (MRNA) looks expensive on cached numbers — not a short thesis.
Latest reported MRNA revenue for 2025-12-31 was $1.94B. Net income was -$2.82B. Revenue was down 39.9% from 2024-12-31 to 2025-12-31. MRNA currently screens at market cap $24.52B.
MRNA currently screens at market cap $24.52B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MRNA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MRNA stock page for the full model, not this heading.
Not investment advice.